RedHill Biopharma - Commercial stage, GI-focused R&D pharma
2017 saw RedHill transformed from a pure drug developer into a commercial-stage, revenue-generating, specialty pharma company focused on gastrointestinal (GI) indications. During 2017, it began marketing three GI products in the US and we expect a rapid sales build-up. Two other important share price catalysts in 2018 will be the data readouts from two Phase III trials – RHB-104 for Crohn’s disease (CD) and TALICIA for H. pylori infection. Following several modifications to our NPV aligning with RedHill’s latest R&D update, we value the company at $410m or $19.2/ADS (vs $21.1/ADS).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.